Cardiome Will Develop Eli Lilly Compound to Treat Cardiogenic Shock

 

May 1, 2007

May 1, 2007 — Cardiome Pharma Corp. says this week it has received exclusive worldwide rights to Eli Lilly & Co.'s protein GED-aPC, which will initially be developed as cardiogenic shock treatment.

The Associated Press reports that Cardiome will pay Eli Lilly $20 million upfront and future development milestones of up to $40 million. Eli Lilly is entitled to royalty payments if the molecule is commercialized. Cardiome said clinical costs for the compound will be about $5 million in 2007.

The compound has anti-inflammatory and anti-thrombotic properties. Eli Lilly has already finished an early-stage clinical trial on the drug.

The content of this field is kept private and will not be shown publicly.
Type the characters you see in this picture. (verify using audio)
Type the characters you see in the picture above; if you can't read them, submit the form and a new image will be generated. Not case sensitive.